儿童急性淋巴细胞白血病的免疫治疗

Journal of cancer immunology Pub Date : 2020-12-31 DOI:10.33696/CANCERIMMUNOL.2.028

Julie M. Asare, C. Rabik, S. Cooper, P. Brown

{"title":"儿童急性淋巴细胞白血病的免疫治疗","authors":"Julie M. Asare, C. Rabik, S. Cooper, P. Brown","doi":"10.33696/CANCERIMMUNOL.2.028","DOIUrl":null,"url":null,"abstract":"Approximately 85% of ALL cases are B-ALL [2]. Cure rates for B-ALL significantly rose over the past five decades from 10% to 90% [1-3] due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification [3]. Despite these successes, about 2% of patients are refractory to chemotherapy and another 10% to 15% of patients will relapse [4]. Treatment for these patients remains a therapeutic challenge. Event free survival for Abstract","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy in Pediatric Acute Lymphoblastic Leukemia\",\"authors\":\"Julie M. Asare, C. Rabik, S. Cooper, P. Brown\",\"doi\":\"10.33696/CANCERIMMUNOL.2.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Approximately 85% of ALL cases are B-ALL [2]. Cure rates for B-ALL significantly rose over the past five decades from 10% to 90% [1-3] due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification [3]. Despite these successes, about 2% of patients are refractory to chemotherapy and another 10% to 15% of patients will relapse [4]. Treatment for these patients remains a therapeutic challenge. Event free survival for Abstract\",\"PeriodicalId\":73633,\"journal\":{\"name\":\"Journal of cancer immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/CANCERIMMUNOL.2.028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/CANCERIMMUNOL.2.028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

大约85%的ALL病例是B-ALL[2]。B-ALL的治愈率在过去五十年中从10%显著上升到90%[1-3]，这是由于多智能体化疗方案、中枢神经系统预防和更好的风险分层[3]。尽管取得了这些成功，但约有2%的患者对化疗顽固，另有10%至15%的患者会复发[4]。这些患者的治疗仍然是一个治疗挑战。抽象的无事件生存

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immunotherapy in Pediatric Acute Lymphoblastic Leukemia

Approximately 85% of ALL cases are B-ALL [2]. Cure rates for B-ALL significantly rose over the past five decades from 10% to 90% [1-3] due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification [3]. Despite these successes, about 2% of patients are refractory to chemotherapy and another 10% to 15% of patients will relapse [4]. Treatment for these patients remains a therapeutic challenge. Event free survival for Abstract

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of cancer immunology

自引率

0.00%

发文量